Safety evaluation of moxidectin sustained-release injectable in 10-week-old puppies.
A study was conducted to evaluate the safety of a commercial formulation of moxidectin sustained-release injectable for dogs (ProHeart 6, Fort Dodge Animal Health) administered as a single subcutaneous dose to 10-week-old puppies. Twelve male and 12 female purpose-bred beagles 10 weeks of age were blocked by weight within gender and randomly allocated to three treatment groups. Puppies in two groups were treated with moxidectin sustained-release injectable for dogs at three or five times the labeled dose rate of 0.17 mg moxidectin/kg. The third group was treated with saline solution as controls. Physical and neurologic status, hematologic parameters, clinical chemistries, urine samples, body weight, and food consumption were evaluated before and up to 12 weeks after treatment. When compared to controls, mild depression of erythropoiesis, characterized by reduced hemoglobin, reticulocytes, erythrocytes, and hematocrit, was noted in puppies treated with five times the label dose of moxidectin sustained-release injectable. Values for these parameters remained within normal ranges and increased during the study, but at a reduced rate relative to saline-treated controls. Other parameters evaluated remained within normal limits for all treatment groups. Based on results of this study, the no observed adverse effect level for moxidectin sustained-release injectable (ProHeart 6) treatment in 10-week-old puppies was determined to be three times the recommended rate.
Heaney
Kathleen
K
Fort Dodge Animal Health, P.O. Box 5366 Princeton, NJ 08543, USA. heaneyk@pt.fdah.com
Lindahl
Ronald G
RG
D000818:Animals; D003692:Delayed-Action Preparations; D004183:Dirofilaria immitis / Q000187:drug effects*; D004184:Dirofilariasis / Q000517:prevention & control*; D004283:Dog Diseases / Q000517:prevention & control*; D004285:Dogs; D005260:Female; D005369:Filaricides / Q000009:adverse effects / Q000494:pharmacology*; D007279:Injections, Subcutaneous / Q000662:veterinary; D018942:Macrolides / Q000009:adverse effects / Q000494:pharmacology; D008297:Male; D019055:No-Observed-Adverse-Effect Level; D012449:Safety; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D005369:Filaricides; D018942:Macrolides; C027837:moxidectin